Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

**CURRENT STATUS:** UNDER REVIEW

*BMC Pharmacology and Toxicology*  ▶ *BMC Series*

Takashi Ueda  
Hyogo College of Medicine  
✉ taka76@hyo-med.ac.jp  
*Corresponding Author*  
ORCID: https://orcid.org/0000-0002-5176-9050

Yoshio Takesue  
Hyogo College of Medicine

Kazuhiko Nakajima  
Hyogo College of Medicine

Kaoru Ichiki  
Hyogo College of Medicine

Kaori Ishikawa  
Hyogo College of Medicine

Yoshiko Takai  
Hyogo College of Medicine

Kumiko Yamada  
Hyogo College of Medicine

Toshie Tsuchida  
Hyogo College of Medicine

Naruhito Otani  
Hyogo College of Medicine

Yoshiko Takahashi  
Hyogo College of Medicine Hospital
Mika Ishihara
Hyogo College of Medicine Hospital

Shingo Takubo
Hyogo College of Medicine Hospital

Hiroki Ikeuchi
Hyogo College of Medicine

Motoi Uchino
Hyogo College of Medicine

Takeshi Kimura
Hyogo College of Medicine Hospital

DOI:
10.21203/rs.3.rs-24637/v1

SUBJECT AREAS
Clinical Pharmacology  Toxicology

KEYWORDS
Teicoplanin; Loading dose; Trough concentration; Hypoalbuminemia; Therapeutic drug monitoring
Abstract

**Background:** A trough concentration ($C_{\text{min}}$) $\geq 20 \, \mu\text{g/mL}$ of teicoplanin is recommended for the treatment of serious methicillin-resistant *Staphylococcus aureus* (MRSA) infections. However available data are limited because it is difficult to attain this target $C_{\text{min}}$.

**Methods:** Pharmacokinetics and adverse events were evaluated in all eligible patients. For clinical efficacy, patients who had bacteremia/complicated MRSA infections were analyzed. The primary endpoint for clinical efficacy was an early clinical response at 72–96 h after the start of therapy. Five doses of 12 mg/kg or 10 mg/kg was administered as an enhanced or conventional high loading dose regimen, respectively. The $C_{\text{min}}$ was obtained at 72 h after the first dose.

**Results:** Overall, 512 patients were eligible, and 76 patients were analyzed for treatment efficacy. The proportion of patients achieving the target $C_{\text{min}}$ range (20–40 $\mu\text{g/mL}$) by the enhanced regimen was significantly higher than for the conventional regimen (75.2% versus 41.0%, $p < 0.001$). In multivariate analysis, $C_{\text{min}} \geq 20 \, \mu\text{g/mL}$ was an independent factor for an early clinical response (odds ratio 3.95, 95% confidence interval 1.25–12.53). There was no significant difference in the occurrence of adverse events between patients who did or did not achieve a $C_{\text{min}} \geq 20 \, \mu\text{g/mL}$.

**Conclusion:** A target $C_{\text{min}} \geq 20 \, \mu\text{g/mL}$ might improve early clinical responses during the treatment of difficult MRSA infections using 12 mg/kg teicoplanin for five doses within the initial 3 days.

**Background**

Teicoplanin is a glycopeptide antibiotic used for the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA). This antibiotic is currently available in many countries in Europe, Asia, and South America but not in the United States. Because of its long half-life, a loading dose of teicoplanin is required to achieve early optimal serum levels [1]. The ratio of the area under the concentration-time curve to the minimum inhibitory concentration (AUC/MIC) was used to determine the pharmacokinetic/pharmacodynamic (PK/PD) index associated with teicoplanin therapy [2]. In a clinical setting, the trough concentration ($C_{\text{min}}$) is used as a surrogate marker to predict adequate treatment effects [3].
Traditionally, a $C_{\text{min}} \geq 10 \, \mu g/mL$ is considered appropriate for MRSA infections [4]. Recently, it was reported that a teicoplanin $C_{\text{min}} \geq 15 \, \mu g/mL$ was required for the successful clinical treatment of MRSA infection [5, 6], whereas a $C_{\text{min}} \geq 20 \, \mu g/mL$ was recommended for other serious infections such as bone and joint infections and infective endocarditis [7, 8]. Wilson et al. [7] showed that treatment in 6/10 staphylococcal infective endocarditis patients failed if the $C_{\text{min}}$ was $< 20 \, \mu g/mL$ compared with 1/11 where the $C_{\text{min}}$ was $\geq 20 \, \mu g/mL$. Byrne et al. [9] reported that the mean $C_{\text{min}}$ on days 3-7 in successful cases was 19.6 mg/L, suggesting that a target $C_{\text{min}} \geq 20$ mg/L would be required for the clinically acceptable probability of a successful outcome. However, Harding et al. [10] reported that with the standard dose, most patients had a $C_{\text{min}} < 15 \, \mu g/mL$; therefore, they could not conclude that a $C_{\text{min}} \geq 20 \, \mu g/mL$ would add further benefit. Byrne et al. [9] reported that although their hospital adopted higher than conventional doses in patients with hematological malignancy with the aim of achieving a $C_{\text{min}} \geq 20 \, \mu g/mL$, attainment of the target concentration in the first week of therapy was poor.

A dosing regimen of teicoplanin to reach a $C_{\text{min}} \geq 20 \, \mu g/mL$ should be used for patients with severe, deep-seated or complicated MRSA infections. For bone and joint infections and infective endocarditis, teicoplanin 12 mg/kg body weight every 12 h for three-to-five doses is recommended. In Monte Carlo simulations, a high probability of attaining the target $C_{\text{min}}$ of 20 $\mu g/mL$ was observed using a regimen of 12 mg/kg administered at 12-h intervals for five doses, but not when using four doses [11]. Byrne et al. [12] reported the recommended loading dose to achieve a $C_{\text{min}} \geq 20 \, \mu g/mL$ based on population PK analysis was 12 mg/kg administered every 12 h for five doses in patients with a body weight of 70 kg and serum albumin level of 3.0 mg/dL. This enhanced loading dosing regimen was considered optimal on the basis of these simulation analyses. The aim of this study was to evaluate the clinical efficacy and safety when the target teicoplanin $C_{\text{min}}$ was set as $\geq 20 \, \mu g/mL$ in patients with complicated MRSA infections including bacteremia using a loading dose regimen of 12 mg/kg administered every 12 h for five doses.
Methods

Patients

This retrospective study was conducted between June 2015 and May 2019, and was approved by the Institutional Review Board of Hyogo College of Medicine (No. 3266). Adult patients who were treated with teicoplanin, and in whom therapeutic drug monitoring (TDM) was performed, were included in the study. Exclusion criteria were patients with known hypersensitivity to teicoplanin, pregnancy, below the age of 18 years, and requirement of intermittently hemodialysis and continuous renal replacement therapy. The analysis of $C_{\text{min}}$ and the safety population included all eligible patients. The analysis of the clinical efficacy population included patients 1) who had bacteremia or complicated infections [ventilator associated pneumonia (VAP), osteomyelitis and arthritis infection, and central nervous system infection] by MRSA, 2) who received at least 4 days of teicoplanin treatment, 3) who did not receive any concomitant antibiotics with anti-MRSA activity, and 4) who did not receive the above mentioned antibiotics for $>24$ h within the previous 3 days.

A diagnosis for each infection was based on definitions in the guidelines issued by the National Healthcare Safety Network [13]. Infections with at least one of the following signs were analyzed: core temperature $>37.8^\circ$C, total peripheral white blood cell (WBC) count $>10,000/\text{mm}^3$, or C-reactive protein (CRP) $>3.0$ mg/dL. The minimum inhibitory concentration (MIC) of teicoplanin was measured by microdilution methods in accordance with the Clinical and Laboratory Standards Institute testing guidelines (M02 and M07, 2018) [14]. MIC break-points set by the European Committee on Antimicrobial Susceptibility Testing were adopted in this study, and antimicrobial resistance was defined as MIC $\geq 4$ µg/mL. The estimated glomerular filtration rate (eGFR) was calculated using the following formula developed by the Japanese Society of Nephrology $[\text{eGFR (mL/min/1.73 m}^2\text{)} = 194 \times \text{serum creatinine}^{-1.094} \times \text{age}^{-0.287} \times 0.739 \text{ (for females)}] [15]$

Administration plan in patients with conventional and enhanced high loading dose regimens

The target initial trough concentration ($C_{\text{min}}$) was 15–30 µg/mL between June 2015 and May 2018, and
20–40 µg/mL in patients with bacteremia/complicated MRSA infections between June 2018 and May 2019. According to these target $C_{\text{min}}$, we conducted two different teicoplanin dose regimens for 3 consecutive days as follows. A conventional high loading dose regimen was used for patients with a target $C_{\text{min}}$ 15–30 µg/mL, and the enhanced high loading dose regimen was used for patients with a target $C_{\text{min}}$ 20–40 µg/mL.

1. Conventional high loading dose regimen: a loading dose of 10 mg/kg twice daily on the first and second days, followed by 10 mg/kg once daily on the third day in patients whose eGFR was ≥60 ml/min/1.73 m$^2$; a loading dose of 10 mg/kg twice daily on the first day, followed by 10 mg/kg once daily on the second and third days in patients whose eGFR was 40–60 ml/min/1.73 m$^2$; and a loading dose of 10 mg/kg twice daily on the first day, followed by 6.7 mg/kg once daily on the second and third days in patients whose eGFR was <40 ml/min/1.73 m$^2$. Maintenance dosing after the fourth day was 6.7 mg/kg once daily in patients whose eGFR was ≥60 ml/min/1.73 m$^2$; 3.3 mg/kg once daily in patients whose eGFR was 40–60 ml/min/1.73 m$^2$; and 5.0 mg/kg every 2 days in patients whose eGFR was <40 ml/min/1.73 m$^2$.

2. Enhanced high loading dose regimen: a loading dose of 12 mg/kg twice daily on the first and second days, followed by 12 mg/kg once daily on the third day in patients whose eGFR was ≥60 ml/min/1.73 m$^2$; a loading dose of 12 mg/kg twice daily on the first day, followed by 12 mg/kg once daily on the second and third days in patients whose eGFR was 30–60 ml/min/1.73 m$^2$; and a loading dose of 12 mg/kg twice daily on the first day, followed by 12 mg/kg once daily on the second day and 6.7 mg/kg once daily on the third day in patients whose eGFR was <30 ml/min/1.73 m$^2$. The maintenance dosing regimen after the fourth day was 6.7 mg/kg once daily in
patients whose eGFR was ≥60 ml/min/1.73 m²; 5.0 mg/kg once daily in patients whose eGFR was 30–60 ml/min/1.73 m²; and 6.7 mg/kg every 2 days in patients whose eGFR was <30 ml/min/1.73 m².

**Therapeutic drug monitoring and dosage adjustment**

An initial \( C_{\text{min}} \) sample was obtained prior to the administration of teicoplanin on the fourth day (at 72 h after the first dose). The target \( C_{\text{min}} \) was defined as 20–40 \( \mu \)g/mL. The dose of teicoplanin was adjusted according to the initial \( C_{\text{min}} \). Additional loading doses were administered on the fourth day if the initial \( C_{\text{min}} \) was lower than the target \( C_{\text{min}} \). Blood samples were collected in blood-collection tubes without a blood coagulation accelerator and immediately centrifuged at 3000 rpm for 10 min. Teicoplanin was measured using a fluorescence polarization immunoassay with a TDXFLX analyzer (Abbott Japan Co., Tokyo, Japan) and a teicoplanin TDM kit-IBL (OXIS International Inc., Beverly Hills, CA, USA).

**Clinical efficacy**

The primary endpoint was an early clinical response at 72–96 h after the start of teicoplanin therapy. We defined patients as responders if they had a 30% or greater decrease in total peripheral WBC count or CRP, decline of fever (defined as a daily maximum temperature decrease of > 0.3°C for at least two consecutive days in febrile patients), without worsening of clinical features, and did not die within 96 h [16]. Secondary efficacy end points were clinical success at the end of teicoplanin therapy (EOT), which was defined as survival with the resolution or improvement of all core symptoms and signs of infection in each infection to the extent that further antibacterial therapy with anti-MRSA activity was unnecessary. Microbiological assessments were conducted using cultures taken before the start of teicoplanin administration and at the completion of treatment, and microbiological success was defined as “eradication” (pathogen absent in culture) or “presumed eradication” (no material available for culture because the infection was cured or attenuated).

**Adverse events**

Adverse events of nephrotoxicity and hepatotoxicity were evaluated on the fourth day of therapy and
at the end of teicoplanin therapy. Nephrotoxicity was defined as a serum creatinine (Cre) increase >0.5 mg/L or 50% increase from the baseline [17]. Hepatotoxicity was defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels at or above three times the upper limit of normal. If the AST or ALT baseline was abnormal, hepatotoxicity was defined as AST or ALT at or above three times the baseline [18].

**Statistical analysis**

Parametric variables were analyzed using the Student’s t-test, while nonparametric variables were analyzed using the Mann-Whitney U-test or Fisher’s exact test. Multivariate analyses were performed to determine the odds ratio (OR) to achieve the target $C_{\text{min}}$ (≥20 μg/mL) and early clinical responses. The crude OR in univariate analysis was estimated for each variable using the chi-squared test, and potential confounders were examined by cross tabulation. Variables selected by univariate analysis (p < 0.1) were subsequently entered into a stepwise logistic regression model to estimate the magnitude of association [adjusted OR and 95% confidence interval (CI)]. The level of significance was set at p < 0.05. SPSS ver. 24 (SPSS Inc., Chicago, IL, USA) was used to perform statistical analyses.

**Results**

**Patient characteristics**

The number of patients included in the analysis of $C_{\text{min}}$ and the safety population was 512 (363 in the high loading dose regimen group and 149 in the enhanced high loading dose regimen group). Among 139 patients with MRSA infections, 63 were excluded from the efficacy population [26 because of the previous use of antimicrobial agents with anti-MRSA activity and 37 without bacteremia/complicated MRSA infections (skin and soft tissue infection = 21; intra-abdominal infection = 12; urinary tract infection = 4; and sinusitis = 1)]. Thus, 76 patients with bacteremia/complicated MRSA infections were analyzed for treatment efficacy (53 in the high loading dose regimen group and 23 in the enhanced high loading dose regimen group). Teicoplanin MICs were ≤2 μg/mL in all MRSA isolates, and there was no resistant strain. Baseline demographics of enrolled patients with the conventional and enhanced high loading dose regimens are shown in Table 1. The total doses for the initial 3 days
and the maintenance dose after day 4 according to renal function in patients with conventional and enhanced high loading dose regimens are shown in supplemental table 1. The recommended doses and observed administered doses in this study were similar in each renal function category.

**Measurements of C_{min}**

The median C_{min} on the fourth day was 18.3 µg/mL in the conventional high loading dose regimen group, and 24.9 µg/mL in the enhanced high dose loading regimen group (p < 0.001) (Table 2). A similar difference was confirmed in each renal function category (Supplementary table 2). The proportion of patients achieving the target range (20–40 µg/mL) in the enhanced high loading dose regimen was significantly higher than that in the conventional high loading dose regimen (75.2% versus 41.0%, p < 0.001). Even in the enhanced high loading dose regimen group, only 5 of 149 patients had a C_{min} ≥40 µg/mL and no patient experienced a C_{min} ≥60 µg/mL. Additional loading doses were administered if the initial C_{min} was <20 µg/mL (25 of 32 patients, 78.1%). However, the target C_{min} was ≥15 µg/mL in the conventional high loading dose regimen, and additional loading doses were administered if the initial C_{min} was <15 µg/mL (56 of 85 patients, 65.9%).

In the multivariate analysis, enhanced high loading dose regimen (adjusted OR: 7.75, 95% CI: 4.62–13.00) and body mass index ≥25 (adjusted OR: 2.33, 95% CI: 1.24–4.38) were independent factors to achieve an initial C_{min} ≥20 µg/mL. In contrast, hypoalbuminemia (adjusted OR: 0.24, 95% CI: 0.15–0.37), total parenteral nutrition (adjusted OR: 0.54, 95% CI: 0.32–0.92), and surgery within 28 days (adjusted OR: 0.47, 95% CI: 0.30–0.74) decreased the attainment of an initial C_{min} ≥20 µg/mL (Table 3). Although the cut off serum albumin concentration was defined as the median value for hypoalbuminemia, the median C_{min} according to each serum albumin concentration category were 25.7 µg/mL in the ≥3.5 g/dL group; 22.0 µg/mL in the 3.0–3.5 g/dL group; 21.6 µg/mL in the 2.5–3.0 g/dL group; 18.2 µg/mL in the 2.0–2.5 g/dL group; and 16.2 µg/mL in the <2.0 g/dL group. There was a tendency toward a dose response relationship between C_{min} and serum albumin level.

**Clinical efficacy of teicoplanin therapy in patients with complicated MRSA infection**

Fifty-four of 76 patients (71.1%) met the definition for an early clinical response on the fourth day,
and 55 of 76 patients (72.4%) met the definition of clinical success at the end of the therapy. The early clinical response rate in patients with an initial $C_{\text{min}} \geq 20 \, \mu g/mL$ tended to be higher than those with a $C_{\text{min}} < 20 \, \mu g/mL$ [31/39 (79.5%) versus 23/37 (62.2%), $p = 0.096$]. However, there was no significant difference in clinical success at the end of therapy between patients who did and did not achieve an initial $C_{\text{min}} \geq 20 \, \mu g/mL$. The maximum $C_{\text{min}}$ during therapy and the type of regimen did not affect any patient outcomes (Table 4, supplementary table 3). In the multivariate analysis, an initial $C_{\text{min}} \geq 20 \, \mu g/mL$ (adjusted OR: 3.95, 95% CI: 1.25–12.53) and bacteremia (adjusted OR: 4.55, 95% CI: 1.10–18.77) were independent factors for an early clinical response to teicoplanin therapy (Table 5).

### Adverse events related to teicoplanin therapy

In the population used for the assessment of safety, there were no significant differences in the occurrence of adverse events on the fourth day and at the end of therapy between those patients who did and did not achieve an $C_{\text{min}} \geq 20 \, \mu g/mL$ (nephrotoxicity: 2.9% versus 3.4%, $p = 0.739$, and 7.8% versus 7.9%, respectively; hepatotoxicity: 1.6% versus 1.5%, $p = 1.000$, and 2.9% versus 1.5%, $p = 0.366$, respectively) (Table 6). There was no significant difference in the occurrence of adverse events between the two teicoplanin regimens (supplementary table 4).

### Discussion

For bone and joint infections and infective endocarditis, teicoplanin 12 mg/kg body weight every 12 h for three to five doses is recommended$^4$. However, the optimal number of loading doses is unclear. Previously, we demonstrated that a $C_{\text{min}}$ 15–30 $\mu g/mL$ was obtained in 68% of patients (mean body weight approximately 50 kg) with a dosing regimen of 600 mg at 12-h intervals for five doses (total dose of 3000 mg) [6]. However, the mean $C_{\text{min}}$ remained 20.0 $\mu g/mL$, and post-hoc analysis revealed that a target $C_{\text{min}} \geq 20 \, \mu g/mL$ was obtained in less than half of the patients. In a regimen of 12 mg/kg every 12 h for four doses followed by 6 mg/kg once daily, the total dose over 3 days was 54 mg/kg (2700 mg in patients weighing 50 kg), which was less than the total dose of 3000 mg in the regimen using 600 mg for five doses. Therefore, in this study we decided to use 12 mg/kg for five doses in patients with difficult MRSA infections to achieve a target $C_{\text{min}} \geq 20 \, \mu g/mL$. With this enhanced high
loading dose regimen, a significantly higher achievement rate of the target $C_{\text{min}}$ 20–40 µg/mL was observed compared with the conventional regimen (75.2% versus 41.0%, $p < 0.001$). Even with the enhanced loading dose, only a small number of patients had a $C_{\text{min}} > 40$ µg/mL and no patients experienced a $C_{\text{min}} > 60$ µg/mL, which might cause adverse events related to teicoplanin therapy. Because of the adequate teicoplanin concentration, the enhanced loading dose regimen did not result in a high rate of adverse events compared with the conventional loading dose regimen.

In the multivariate analysis, enhanced regimen was an independent factor associated with a $C_{\text{min}} \geq 20$ µg/mL. In contrast, hypoalbuminemia, total parenteral nutrition, and surgery were selected as independent factors for the decreased attainment of a $C_{\text{min}} \geq 20$ µg/mL. Serum albumin concentrations are an important determinant of PK for antibiotics that have a high binding affinity to albumin such as teicoplanin. Lower albumin concentrations are associated with a higher free (unbound) fraction of antibiotic [19], which increase the distribution and clearance of the drug leading to a reduced total drug concentration [20]. Byrne et al. [12] reported that a low serum albumin concentration was associated with the reduced probability of attaining the target total, but not free, $C_{\text{min}}$, which is responsible for antimicrobial activity. Dosing regimens for teicoplanin have been determined according to total $C_{\text{min}}$ targets that may not be appropriate for patients with hypoalbuminemia.

In general, population PK analyses and Monte Carlo simulations are conducted to assess the teicoplanin dosage regimens associated with a high probability of achieving the target $C_{\text{min}}$ [11, 12]. In these PK simulation studies, the sample size is small for clinical studies and therefore no conclusions about the clinical implications are possible. In contrast, the current study used a large sample size. PK analyses were performed in 512 patients including 149 patients that received the enhanced loading dose regimen, and 76 patients with bacteremia/complicated MRSA infections including 23 patients in the enhanced loading dose regimen group were assessed for clinical efficacy. To exclude the impact of an additional loading dose in patients with a low initial $C_{\text{min}}$, the primary endpoint of clinical outcomes was defined as an early clinical response 72–96 h after the start of
teicoplanin therapy. Although, no significant difference in clinical success at the end of therapy was demonstrated between patients who did and did not achieve a $C_{\text{min}} \geq 20 \mu g/mL$, achieving a $C_{\text{min}} \geq 20 \mu g/mL$ was an independent factor for early clinical responses.

There were several limitations in our study. First, this study was conducted retrospectively in a single institution. Second, central catheter-related blood stream infections were included in this study, and a different result may have been obtained for clinical efficacy if only patients with complicated MRSA infections, such as infective endocarditis and bone and joint infections, were analyzed. Third, more measurements are required to assess when the target $C_{\text{min}}$ was actually achieved in the evaluation of clinical efficacy at the end of therapy. Lastly, the maintenance dose might be relatively low in our study, which might affect the clinical efficacy at the end of therapy. Lee et al. [21] demonstrated that significantly higher favorable final clinical response rates were found in patients who received a loading dose followed by increased maintenance doses of 6 mg/kg/12 h. than those with standard maintenance doses of 6 mg/kg/24h.

**Conclusion**

In conclusion, a higher target initial $C_{\text{min}} \geq 20 \mu g/mL$ is likely to be associated with a better early clinical response for the treatment of bacteremia/complicated MRSA infections. To obtain the optimal $C_{\text{min}}$, a teicoplanin regimen of 12 mg/kg for five doses within the initial 3 days is required.

**Declarations**

**Ethics approval and consent to participate** The study was approved by the Institutional Review Board of Hyogo College of Medicine (No. 3266). The institutional review board waived the requirement for informed consent from patients included in this study.

**Consent for publication** Not applicable.

**Availability of data and materials** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests** Y. Takesue received grant support from Shionogi & Co., Ltd., and payment for lectures from Astellas Pharma Inc., and MSD Japan. Other authors have no conflict of interest to declare.
**Funding** This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Authors' contributions** TU was involved in the conception of the study, collection, analysis and interpretation of data, the creation of new software used in the work, draft the work and substantively revised of the manuscript. Y Takesue was involved in the design of the study and draft the work. KN, K Ichiki, K Ishikawa, Y Takai, KY, YW, TT, NO, Y Takahashi, MI, ST, HI, MU and TK contributed to the data collection and interpretation. All authors had substantial input to the drafting and review of the manuscript and approved the final version prior to publication.

**Acknowledgements** We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

**Author details** 1Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. 2Department of Public Health, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. 3Department of Pharmacy, Hyogo College of Medicine Hospital, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. 4Department of Inflammatory Bowel Disease, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.

**References**

1. Outman WR, Nightingale CH, Sweeney KR, Quintiliani R. Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses. Antimicrob Agents Chemother. 1990; 34: 2114-7.

2. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003; 17: 479-501.

3. Roberts JA, Stove V, De Waele JJ, Sipinkoski B, McWhinney B, Ungerer JP, et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug
monitoring targets in critically ill patients: lessons from the DALI Study. Int J Antimicrob Agents. 2014; 43: 423-30. https://doi: 10.1016/j.ijantimicag.2014.01.023.

4. Summary of Product Characteristics for Tagocid. 2016. Available from: https://www.medicines.org.uk/emc/medicine/27321.

5. Ueda T, Takesue Y, Nakajima K, Ichiki K, Doita A, Wada Y, et al. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction. Eur J Clin Microbiol Infect Dis. 2016; 35: 1501-9. https://doi: 10.1007/s10096-016-2691-z.

6. Ueda T, Takesue Y, Nakajima K, Ichki K, Wada Y, Komatsu M, et al. High-dose regimen to achieve novel target trough concentration in teicoplanin. J Infect Chemother. 2014; 20: 43-7. https://doi: 10.1016/j.jiac.2013.08.006.

7. Wilson AP, Grüneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents.1994; 4 Suppl 1: 1-30.

8. Matthews PC, Taylor A, Byren I, Atkins BL. Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic? J Infect. 2007; 55: 408-13.

9. Byrne CJ, Egan S, Fennell JP, O'Byrne P, Enright H, Deasy E, et al. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity. Int J Antimicrob Agents. 2015; 46: 406-12. https://doi: 10.1016/j.ijantimicag.2015.05.019.

10. Harding I, MacGowan AP, White LO, Darley ES, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother. 2000; 45: 835-41.

11. Byrne CJ, Roberts JA, McWhinney B, Ryder SA, Fennell JP, O'Byrne P, et al. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological
malignancy. Clin Microbiol Infect. 2017; 23: 674.e7-674.e13. https://doi:10.1016/j.cmi.2017.02.032.

12. Byrne CJ, Parton T, McWhinney B, Fennell JP, O'Byrne P, Deasy E, et al. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. J Antimicrob Chemother. 2018; 73: 995-1003. https://doi: 10.1093/jac/dkx473.

13. CDC/NHSN surveillance definitions for surgical site infections. Centers for Disease Control and Prevention website: 
http://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf. Published January 2020. Accessed December 23, 2019.

14. Wayne, PA. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 28th Edition Informational Supplement. CLSI, 2018; M02 and M07

15. Matsuo S, Imai E, Horio M. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–92.

16. Matsumoto T, Hanaki H, Kimura T, Nemoto M, Higashihara M, Yokota H, et al. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study. J Infect Chemother. 2013; 19: 128-37.

17. Rybak M, Lomaestro B, Rotschafer JC, Moeller R Jr, Craig W, Billeter M. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66: 82-98.

18. Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin Pharmacol Ther. 2009; 85: 331-4.
19. Yano R, Nakamura T, Tsukamoto H, Igarashi T, Goto N, Wakiya Y, et al. Variability in teicoplanin protein binding and its prediction using serum albumin concentrations. Ther Drug Monit. 2007; 29: 399-403.

20. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011; 50: 99-110. https://doi: 10.2165/11539220-000000000-00000

21. Lee CH, Tsai CY, Li CC, Chien CC, Liu JW. Teicoplanin therapy for MRSA bacteraemia: a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes. J Antimicrob Chemother. 2015; 70: 257-63. https://doi: 10.1093/jac/dku335.

Tables
Due to technical limitations the Tables are available as a download in the Supplementary Files.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

TEIC12mgkgSupplementaryTable20200309.pptx
TEIC12mgkgTable20200309.pptx
Availabilityofdataandmaterials.xlsx